{
  "trial_id": "NCT03334214",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, body mass index (BMI), Hemoglobin A1C (HbA1c), liver fat percentage, duration of Type 2 Diabetes Mellitus, stable dose of Oral Antidiabetic Therapy, stable body weight, history of solid organ transplantation, history of renal dialysis, history of drug or alcohol abuse, use of concomitant medications, use of anticoagulant/antiplatelet agents, use of non-steroidal anti-inflammatory drugs, use of obeticholic acid or ursodeoxycholic acid.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Liver Fat Percentage (Randomized Population)",
          "liver fat percentage"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity",
        "Liver Fat Percentage (Per Protocol Population)"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "Hemoglobin A1C (HbA1c)",
        "duration of Type 2 Diabetes Mellitus",
        "stable dose of Oral Antidiabetic Therapy",
        "stable body weight",
        "history of solid organ transplantation",
        "history of renal dialysis",
        "history of drug or alcohol abuse",
        "use of concomitant medications",
        "use of anticoagulant/antiplatelet agents",
        "use of non-steroidal anti-inflammatory drugs",
        "use of obeticholic acid or ursodeoxycholic acid"
      ]
    },
    "processed-gen-response": "Age, sex, body mass index (BMI), Hemoglobin A1C (HbA1c), liver fat percentage, duration of Type 2 Diabetes Mellitus, stable dose of Oral Antidiabetic Therapy, stable body weight, history of solid organ transplantation, history of renal dialysis, history of drug or alcohol abuse, use of concomitant medications, use of anticoagulant/antiplatelet agents, use of non-steroidal anti-inflammatory drugs, use of obeticholic acid or ursodeoxycholic acid."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Body Mass Index, HbA1c, Duration of Diabetes, Liver Fat Percentage, Use of Oral Antidiabetic Therapy, Systolic Blood Pressure, Diastolic Blood Pressure,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Liver Fat Percentage (Randomized Population)",
          "Liver Fat Percentage"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Liver Fat Percentage (Per Protocol Population)"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "HbA1c",
        "Duration of Diabetes",
        "Use of Oral Antidiabetic Therapy",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Body Mass Index, HbA1c, Duration of Diabetes, Liver Fat Percentage, Use of Oral Antidiabetic Therapy, Systolic Blood Pressure, Diastolic Blood Pressure"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Hemoglobin A1C, Liver Fat Percentage, Diabetes Duration, Oral Antidiabetic Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Liver Fat Percentage (Randomized Population)",
          "Liver Fat Percentage"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Liver Fat Percentage (Per Protocol Population)"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Body Mass Index",
        "Hemoglobin A1C",
        "Diabetes Duration",
        "Oral Antidiabetic Therapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Hemoglobin A1C, Liver Fat Percentage, Diabetes Duration, Oral Antidiabetic Therapy"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), hemoglobin A1C (HbA1c), liver fat percentage, type 2 diabetes mellitus duration, oral antidiabetic therapy use, medical history, physical examination findings, laboratory values, weight, height.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Liver Fat Percentage (Randomized Population)",
          "liver fat percentage"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity",
        "Liver Fat Percentage (Per Protocol Population)"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "body mass index (BMI)",
        "hemoglobin A1C (HbA1c)",
        "type 2 diabetes mellitus duration",
        "oral antidiabetic therapy use",
        "medical history",
        "physical examination findings",
        "laboratory values",
        "weight",
        "height"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), hemoglobin A1C (HbA1c), liver fat percentage, type 2 diabetes mellitus duration, oral antidiabetic therapy use, medical history, physical examination findings, laboratory values, weight, height."
  }
}